Back to Market Feed

Product Information

OPZELURA 1.5% CREAM is a brand product labeled by Incyte Corporation, priced at $33.9982 per GM under NDC 50881000705. Its NADAC has been published 218 times since Jun 22, 2022.

FDA first approved this application on Sep 21, 2021.

OPZELURA 1.5% CREAM

ruxolitinib
$33.9982per GM

Strength

15 mg/g

Manufacturer

Incyte Corporation

NDC

50881000705

Classification

Brand

Dosage Form

CREAM

Route

TOPICAL

Effective Date

8/19/2026

Active Ingredients

RUXOLITINIB PHOSPHATE

Approval Type

New Drug (NDA)

FDA Application

NDA215309

FDA Approved

9/21/2021

On Market Since

9/21/2021

Pharmacological Classes

Janus Kinase Inhibitor
Janus Kinase Inhibitors
Kinase Inhibitor

Price Statistics

The NADAC for OPZELURA 1.5% CREAM has been published 218 times since Jun 22, 2022, and over the history we have for it it has risen 8.8%. The table below summarizes its recorded NADAC range and movement.

Current price$33.9982 per GM
All-time high$34.1433 (May 13, 2026)
All-time low$31.2358 (Jun 22, 2022)
52-week high$34.1433
52-week low$33.4719
Median price$32.8437
Average price$32.8071
Largest weekly change+3.0% (Jan 18, 2023)
Weeks tracked218
Tracking sinceJun 22, 2022

Price History

1W

+0.0%

1M

-0.1%

3M

-0.1%

6M

-0.4%

1Y

+1.5%

3Y

+5.7%

5Y

N/A

All

+8.8%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ruxolitinib market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

ZORTRESS 0.5 MG TABLET
Brand
00078041420•Novartis Pharmaceuticals Corporation
$17.8041
per EA
ZORTRESS 0.75 MG TABLET
Brand
00078041520•Novartis Pharmaceuticals Corporation
$27.0419
per EA
XELJANZ 5 MG TABLET
Brand
00069100101•Pfizer Inc.
$73.6658
per EA
GLEEVEC 100 MG TABLET
Brand
00078040134•Novartis Pharmaceuticals Corporation
$90.8197
per EA
OLUMIANT 2 MG TABLET
Brand
00002418230•Eli Lilly and Company
$92.5328
per EA
TASIGNA 200 MG CAPSULE
Brand
00078052651•Novartis Pharmaceuticals Corporation
$94.1452
per EA
TASIGNA 200 MG CAPSULE
Brand
00078052687•Novartis Pharmaceuticals Corporation
$94.1452
per EA
XELJANZ 10 MG TABLET
Brand
00069100201•Pfizer Inc.
$103.9384
per EA
RHOPRESSA 0.02% OPHTH SOLUTION
Brand
70727049725•Alcon Laboratories, Inc.
$131.7573
per ML
ROCKLATAN 0.02%-0.005% EYE DRP
Brand
70727052925•Alcon Laboratories, Inc.
$139.4419
per ML

Frequently asked questions

What is the NADAC price of OPZELURA 1.5% CREAM?

The current National Average Drug Acquisition Cost (NADAC) for OPZELURA 1.5% CREAM, manufactured by Incyte Corporation, is $33.9982 per GM (NDC 50881000705), effective Aug 19, 2026.

How has the price of OPZELURA 1.5% CREAM changed over time?

Over the history we have for it, the NADAC for OPZELURA 1.5% CREAM has risen 8.8%. It has been tracked across 218 weekly CMS publications since Jun 22, 2022.

What are the highest and lowest recorded NADAC prices for OPZELURA 1.5% CREAM?

Since Jun 22, 2022, the NADAC for OPZELURA 1.5% CREAM has ranged from a low of $31.2358 (Jun 22, 2022) to a high of $34.1433 (May 13, 2026), with a median of $32.8437 per GM.

Are there cheaper alternatives to OPZELURA 1.5% CREAM?

No other NADAC-published product currently shares the active ingredient and strength of OPZELURA 1.5% CREAM in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures OPZELURA 1.5% CREAM?

OPZELURA 1.5% CREAM (NDC 50881000705) is labeled by Incyte Corporation, and CMS classifies it as a brand product.